Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006

Helio S. Sader, Paul D Fey, Douglas N. Fish, Ajit P. Limaye, George Pankey, James Rahal, Michael J. Rybak, David R. Snydman, Lisa L. Steed, Ken Waites, Ronald N. Jones

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Vancomycin MIC creep has been reported by some institutions but not confirmed in large surveillance studies. We evaluated the possible occurrence of MIC creep when testing vancomycin and daptomycin against methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) by using precise incremental reference MIC methods. Nine hospitals (one in each U.S. census region) randomly selected bloodstream MRSA strains (target, 40/year) from 2002 to 2006. MICs were determined by the reference broth microdilution method using incremental dilutions (eight for each log2 dilution step). Isolates for which vancomycin MICs were >1 μg/ml were typed by pulsed-field gel electrophoresis (PFGE). The vancomycin MIC mode was either 0.625 μg/ml (for eight hospitals) or 0.813 μg/ml (for one hospital), and vancomycin MIC results for 72.9% of strains were between 0.563 and 0.688 μg/ml. No yearly variation in the central tendency of vancomycin MICs for the wild-type population in any medical center was observed; however, when data were analyzed by the geometric mean statistic, vancomycin MIC increases (at three sites) and declines (at three sites) were observed. The daptomycin MIC mode varied from 0.156 μg/ml (2003 to 2005) to 0.219 μg/ml (2002 and 2006), and MIC results for 83.5% (80.3 to 89.2% in each of the centers) of isolates fell between these values. Among PFGE-typed strains, 43 of 55 (78%; from seven hospitals) showed a pattern consistent with that of the USA100 clone, which was represented by all strains from two hospitals and 64 to 88% of strains from five other medical centers; only one strain (2%) was USA300. In conclusion, the perception of MIC creep may vary according to the methods used to analyze the data. Geometric mean MIC data revealed a possible, very-low-level MIC creep at three of nine sites over the 5-year period, which was not evident using modal MICs or the data from all nine hospitals (+0.02 μg/ml). The occurrence of isolates for which the vancomycin MIC was >1 μg/ml was very unusual, with no increased trend, but these organisms were usually clonal (USA100).

Original languageEnglish (US)
Pages (from-to)4127-4132
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume53
Issue number10
DOIs
StatePublished - Oct 1 2009

Fingerprint

Daptomycin
Vancomycin
Methicillin-Resistant Staphylococcus aureus
Pulsed Field Gel Electrophoresis
Oxacillin
Censuses
Clone Cells

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006. / Sader, Helio S.; Fey, Paul D; Fish, Douglas N.; Limaye, Ajit P.; Pankey, George; Rahal, James; Rybak, Michael J.; Snydman, David R.; Steed, Lisa L.; Waites, Ken; Jones, Ronald N.

In: Antimicrobial Agents and Chemotherapy, Vol. 53, No. 10, 01.10.2009, p. 4127-4132.

Research output: Contribution to journalArticle

Sader, Helio S. ; Fey, Paul D ; Fish, Douglas N. ; Limaye, Ajit P. ; Pankey, George ; Rahal, James ; Rybak, Michael J. ; Snydman, David R. ; Steed, Lisa L. ; Waites, Ken ; Jones, Ronald N. / Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006. In: Antimicrobial Agents and Chemotherapy. 2009 ; Vol. 53, No. 10. pp. 4127-4132.
@article{d204fe79a7194161b0a2ccceccd77e81,
title = "Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006",
abstract = "Vancomycin MIC creep has been reported by some institutions but not confirmed in large surveillance studies. We evaluated the possible occurrence of MIC creep when testing vancomycin and daptomycin against methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) by using precise incremental reference MIC methods. Nine hospitals (one in each U.S. census region) randomly selected bloodstream MRSA strains (target, 40/year) from 2002 to 2006. MICs were determined by the reference broth microdilution method using incremental dilutions (eight for each log2 dilution step). Isolates for which vancomycin MICs were >1 μg/ml were typed by pulsed-field gel electrophoresis (PFGE). The vancomycin MIC mode was either 0.625 μg/ml (for eight hospitals) or 0.813 μg/ml (for one hospital), and vancomycin MIC results for 72.9{\%} of strains were between 0.563 and 0.688 μg/ml. No yearly variation in the central tendency of vancomycin MICs for the wild-type population in any medical center was observed; however, when data were analyzed by the geometric mean statistic, vancomycin MIC increases (at three sites) and declines (at three sites) were observed. The daptomycin MIC mode varied from 0.156 μg/ml (2003 to 2005) to 0.219 μg/ml (2002 and 2006), and MIC results for 83.5{\%} (80.3 to 89.2{\%} in each of the centers) of isolates fell between these values. Among PFGE-typed strains, 43 of 55 (78{\%}; from seven hospitals) showed a pattern consistent with that of the USA100 clone, which was represented by all strains from two hospitals and 64 to 88{\%} of strains from five other medical centers; only one strain (2{\%}) was USA300. In conclusion, the perception of MIC creep may vary according to the methods used to analyze the data. Geometric mean MIC data revealed a possible, very-low-level MIC creep at three of nine sites over the 5-year period, which was not evident using modal MICs or the data from all nine hospitals (+0.02 μg/ml). The occurrence of isolates for which the vancomycin MIC was >1 μg/ml was very unusual, with no increased trend, but these organisms were usually clonal (USA100).",
author = "Sader, {Helio S.} and Fey, {Paul D} and Fish, {Douglas N.} and Limaye, {Ajit P.} and George Pankey and James Rahal and Rybak, {Michael J.} and Snydman, {David R.} and Steed, {Lisa L.} and Ken Waites and Jones, {Ronald N.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1128/AAC.00616-09",
language = "English (US)",
volume = "53",
pages = "4127--4132",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. Medical Centers from 2002 to 2006

AU - Sader, Helio S.

AU - Fey, Paul D

AU - Fish, Douglas N.

AU - Limaye, Ajit P.

AU - Pankey, George

AU - Rahal, James

AU - Rybak, Michael J.

AU - Snydman, David R.

AU - Steed, Lisa L.

AU - Waites, Ken

AU - Jones, Ronald N.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Vancomycin MIC creep has been reported by some institutions but not confirmed in large surveillance studies. We evaluated the possible occurrence of MIC creep when testing vancomycin and daptomycin against methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) by using precise incremental reference MIC methods. Nine hospitals (one in each U.S. census region) randomly selected bloodstream MRSA strains (target, 40/year) from 2002 to 2006. MICs were determined by the reference broth microdilution method using incremental dilutions (eight for each log2 dilution step). Isolates for which vancomycin MICs were >1 μg/ml were typed by pulsed-field gel electrophoresis (PFGE). The vancomycin MIC mode was either 0.625 μg/ml (for eight hospitals) or 0.813 μg/ml (for one hospital), and vancomycin MIC results for 72.9% of strains were between 0.563 and 0.688 μg/ml. No yearly variation in the central tendency of vancomycin MICs for the wild-type population in any medical center was observed; however, when data were analyzed by the geometric mean statistic, vancomycin MIC increases (at three sites) and declines (at three sites) were observed. The daptomycin MIC mode varied from 0.156 μg/ml (2003 to 2005) to 0.219 μg/ml (2002 and 2006), and MIC results for 83.5% (80.3 to 89.2% in each of the centers) of isolates fell between these values. Among PFGE-typed strains, 43 of 55 (78%; from seven hospitals) showed a pattern consistent with that of the USA100 clone, which was represented by all strains from two hospitals and 64 to 88% of strains from five other medical centers; only one strain (2%) was USA300. In conclusion, the perception of MIC creep may vary according to the methods used to analyze the data. Geometric mean MIC data revealed a possible, very-low-level MIC creep at three of nine sites over the 5-year period, which was not evident using modal MICs or the data from all nine hospitals (+0.02 μg/ml). The occurrence of isolates for which the vancomycin MIC was >1 μg/ml was very unusual, with no increased trend, but these organisms were usually clonal (USA100).

AB - Vancomycin MIC creep has been reported by some institutions but not confirmed in large surveillance studies. We evaluated the possible occurrence of MIC creep when testing vancomycin and daptomycin against methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) by using precise incremental reference MIC methods. Nine hospitals (one in each U.S. census region) randomly selected bloodstream MRSA strains (target, 40/year) from 2002 to 2006. MICs were determined by the reference broth microdilution method using incremental dilutions (eight for each log2 dilution step). Isolates for which vancomycin MICs were >1 μg/ml were typed by pulsed-field gel electrophoresis (PFGE). The vancomycin MIC mode was either 0.625 μg/ml (for eight hospitals) or 0.813 μg/ml (for one hospital), and vancomycin MIC results for 72.9% of strains were between 0.563 and 0.688 μg/ml. No yearly variation in the central tendency of vancomycin MICs for the wild-type population in any medical center was observed; however, when data were analyzed by the geometric mean statistic, vancomycin MIC increases (at three sites) and declines (at three sites) were observed. The daptomycin MIC mode varied from 0.156 μg/ml (2003 to 2005) to 0.219 μg/ml (2002 and 2006), and MIC results for 83.5% (80.3 to 89.2% in each of the centers) of isolates fell between these values. Among PFGE-typed strains, 43 of 55 (78%; from seven hospitals) showed a pattern consistent with that of the USA100 clone, which was represented by all strains from two hospitals and 64 to 88% of strains from five other medical centers; only one strain (2%) was USA300. In conclusion, the perception of MIC creep may vary according to the methods used to analyze the data. Geometric mean MIC data revealed a possible, very-low-level MIC creep at three of nine sites over the 5-year period, which was not evident using modal MICs or the data from all nine hospitals (+0.02 μg/ml). The occurrence of isolates for which the vancomycin MIC was >1 μg/ml was very unusual, with no increased trend, but these organisms were usually clonal (USA100).

UR - http://www.scopus.com/inward/record.url?scp=70349345819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349345819&partnerID=8YFLogxK

U2 - 10.1128/AAC.00616-09

DO - 10.1128/AAC.00616-09

M3 - Article

C2 - 19635961

AN - SCOPUS:70349345819

VL - 53

SP - 4127

EP - 4132

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -